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Effect of amygdalin on the treatment and  
recurrence of endometriosis in an experimental  
rat study
Abstract
Background: Endometriosis is an aggressive disorder and associated 
with infertility, pelvic pain and intra-abdominal adhesions in women of 
reproductive age. Women with endometriosis has the potential risk of recur-
rence ranging from 21.5% in two years to 50% in five years after recovery 
period. � erefore, there is a certain re�uirement for new drugs as an alter-
native therapy to the current ones.
Aim: �e aim of the present study is to compare the effects of amygdalin 
and leuprolide acetate on endometriosis development and recurrence in rats.
Study Design: Animal experiment
Methods: A total of 30 adult female rats were enrolled. Induction of 
endometriosis was performed by implanting endometriotic focci on the peri-
toneal side of the abdominal wall. Before amygdalin or leuprolide acetate 
treatment one of the implant was removed for histopathological analysis, 
and rats were randomly divided into three groups. Saline (Group 1), amyg-
dalin (Group 2), and leuprolide acetate (Group 3) were administered for 
three weeks. After treatment, one of the remaining three implants was ex-
cised for histopathological evaluation, and all treatments were terminated. 
Estradiol was given after the estradiol induction for the recurrence of endo-
metriosis. Rest of the implanted tissues were removed, then all rats were 
euthanised. �e implant volumes, histopathological injury and fibrosis lev-
els were observed.
Results: �e endometriotic foci volumes in Group 2 and Group 3 were 
significantly lower than in Group 1 (p = 0.001, p = 0.002, respectively). 
�e histopathological injury scores and fibrosis levels were not significantly 
different among the groups (p > 0.05).
Conclusion: �e present study showed that amygdalin has an evident 
effect in the treatment of endometriosis.
INTRODUCTION
Endometriosis is one of the most frequently gynecological disease of the reproductive tract. It is an estrogen-dependent disorder charac-
terized by the implantation and survival of endometrial tissue formed 
by endometrial stromal and epithelial cells at ectopic sites, frequently in 
the peritoneal cavity (1). Additionally, it is an aggressive disorder associ-
ated with infertility, pelvic pain and intra-abdominal adhesions in wom-
en of reproductive age (2). In contrast to the amount of comprehensive 
studies, the pathogenic mechanism underlying the development of this 
condition remains unknown (3,4).
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Management of endometriosis consists of surgical or 
medical therapy. The primary goals of these interven-
tions are the excision of ectopic endometrial tissues, res-
toration of normal anatomical structures, restriction of 
the disease progression, and relief of the symptoms (5,6). 
Medical treatments including oral contraceptives, pro-
gestins, androgens, aromatase inhibitors, gonadotropin 
releasing hormone (GnRH) agonists, anti-tumor necro-
sis factor (TNF), and selective estrogen receptor modu-
lators are widely used; however, no significant differ-
ences have been found from one to another (7). Women 
with endometriosis has the potential risk of recurrence 
ranging from 21.5% in two years to 50% in five years 
after recovery period (8). Therefore, there is a certain 
requirement for new drugs as an alternative therapy to 
the current ones.
Leuprolide acetate is a synthetic form of GnRH re-
ceptor agonists and is clinically used in the treatment of 
endometriosis. It suppresses the production of luteiniz-
ing hormone and follicle-stimulating hormone that sub-
sequently lowers gonadal sex steroid production (9). 
Furthermore, Amygdalin [D-mandelonitrile-b-D-gen-
tiobioside; vitamin B17 (C20H27NO11), also called Lae-
trile] is a cyanogenic glycoside, extracted from Semen 
Persicae, and derived from the aromatic amino acid phe-
nylalanine. It was purified in 1830 from the kernels of 
the bitter almond (Prunus amygdalus) by the French 
chemists named Robiquet and Boutron-Charlard, and 
is intensely contained in the seeds of apricots, peaches, 
and plums. Besides its anti-cancer activity, it has also 
been administered as an alternative treatment for asth-
ma, bronchitis, emphysema, leprosy, diabetes, and pre-
venting and treating of migraine, hypertension. It has 
been thought that amygdalin is also an anti-inflamma-
tory agent (10). A recent study by Jiagang et al. showed 
the influence of amygdalin on the regulation of immune 
system cells during the development of atherosclerosis 
(11). It has been proposed that amygdalin could affect 
the local activity of immune cells which are crucial 
pathogenic factors in the development and progression 
of endometriosis (12).
We hypothesized that amygdalin can suppress the en-
dometriotic implants because of its anti-inflammatory 
effect. A systematic search of the literature revealed that 
there has been no study conducted to show the effects of 
amygdalin on endometriosis. In this context, the aim of 
this study was to evaluate the effects of amygdalin and 
leuprolide acetate on the treatment and recurrence of en-
dometriosis in a rat model.
MATERIALS AND METHODS
Chemicals
Amygdalin and chloral hydrate were purchased from 
Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany. 
Estradiol depot was obtained from Jenapharm, Jena, Ger-
many. Cefazolin sodium was purchased from Eczacıbaşı 
Pharmaceutical, Istanbul, Turkey. Ketamine and xylazine 
were obtained from Alfasan International B.V. Haema-
toxylin Harris and Eosin Y 1% Alcoholic were purchased 
from Atom Scientific Ltd (Manchester, UK). Masson’s 
trichrome was obtained from GBL, Istanbul, Turkey. 
Leuprolide acetate was purchased from Abbott Laborato-
ries, Abbott Park, IL, USA.
Animals
This prospective, randomized, and controlled experi-
mental study was initiated after approval from Animal 
Experimentations Local Ethics Board (2014-HADY-
EK-09). A total of 30 adult female Wistar-Albino rats 
(90 days-old, nulligravid, 250-300 grams) were obtained 
from Experimental Medicine Research Unit. Animals 
were kept in a room maintained at 20 – 24 °C with a 
12-h light-dark cycle (lights on at 06:00 to 18:00) and a 
constant humidity of 40 – 50%. All rats were housed in 
polycarbonate cages and tap water ad libitum. Before the 
endometriosis procedures, the estrus cycle of all animals 
were hormonally synchronized to avoid the possible ef-
fects of steroid release, cell adhesion and growth. The 
estrus cycle was described in the following order: proes-
trus period (several number of epithelial cells with cen-
tric nucleolus), estrus period (cornified epithelial cells 
with no nuclei), metestrus period (leukocytes, mucus, 
and a small number of cornified cells), and diestrus pe-
riod (multiple epithelial cells, mucus, and leukocytes) 
(13). Rats were followed up until successfully complete 




All rats were anesthetized using chloral hydrate 300 
mg/kg intraperitoneally. Endometriosis was induced 
surgically using the method defined by Lebovic and 
Uygur et al (14,15). A 3 cm midline vertical incision was 
performed to enter the abdominal cavity. The right uter-
ine horn was moved away from the cervix up to a loca-
tion approximately 1 cm far from the ovary. The uterine 
horn was incised longitudinally and divided into four 
pieces (0.4 X 0.4cm) consisting of both endometrium 
and myometrium. Pieces were placed in saline solution 
at 37°C and then attached, via the surgical auto-trans-
plantation technique, to the peritoneum with their myo-
metrial side (endometrial side faced to the peritoneal 
cavity) by using 5-0 Vicryl (polyglactin 910, Ethicon, 
Somerville, NJ, USA) on the right and left wall of the 
ventral abdominal side next to an artery. Midline ab-
dominal incision was repaired in a continuous inter-
locking manner using 3-0 Vicryl (polyglactin 910, 
Ethicon, Somerville, NJ, USA). Cefazolin sodium 50 
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mg/kg for three days and estradiol depot 50 mg/kg IM 
twice a week were administered to all rats in the post-
operative period to reduce the duration of endometrio-
sis induction and increase the efficiency (16).
Before amygdalin or LA treatment
This procedure was initiated 21 days after the induc-
tion of endometriosis. The implanted tissues were docu-
mented, and the height, length and width of the tissues 
were measured by a micrometer (Figure 1). The implant 
volume was computed using the formula of ellipsoid vol-
ume (π/6 × length × width × height). One of the four 
implants was excised for histopathological analysis. After 
no significant difference was found between removed tis-
sue volumes following excision the rats were randomly 
divided into three groups as follows: Group 1 received 1 
ml of saline 0.9% (Adeka, Istanbul, Turkey) intraperito-
neally once a week, Group 2 received amygdalin 5 mg/kg 
intraperitoneally once a week, and Group 3 received leu-
prolide acetate 0.0375 mg/kg subcutaneously once a 
week. The doses of amygdalin and leuprolide acetate were 
used as indicated in the study conducted by Guo et al. 
and Dolapciogu et al., respectively (17,18).
After treatment
This procedure was performed 21 days after the previ-
ous one. The height, length and width of the tissues were 
measured by a micrometer, and one of the rest three im-
planted tissues was removed for histopathological evalu-
ation. Thereafter, all medications were terminated and 
remaining estradiol injections for recurrence of endome-
triosis (estradiol depot 50 mg/kg IM twice a week) were 
given until the last operation.
After the estradiol induction  
for the recurrence of endometriosis
After 21 days of estradiol treatment, all rats were eval-
uated for visible signs of recurrent growth under chloral 
hydrate anesthesia, and remaining implanted tissues on 
the abdominal wall were removed. All rats were eutha-
nized by administering ketamine 50 mg/kg and xylazine 
10 mg/kg intraperitoneally.
Histopathological evaluation
The tissue samples harvested from all animals were 
fixed in 10% neutral buffered formalin solution for 24 
hours, quickly upon collection. Samples were dehydrated 
Figure 1. Macroscopic images of endometriotic implant: A – before amydalin or LA treatment; B – after treatment; C – before amydalin or LA 
treatment; D – after treatment.
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and embedded in paraffin for histopathological evalua-
tion. Five μm thick sections were prepared from paraffin-
embedded samples and mounted on glass slides. For 
histopathological assessment under light microscope 
(Nikon Eclipse E600W, Japan), the mounted sections 
were stained with hematoxylin and eosin (H&E) and 
Masson’s trichrome by a pathologist blinded to the study 
groups. A grading scale for the structure of epithelial cells 
in the implants described by Keenan et al. was used to 
determine the histopathological score of the sample tis-
Figure 2. Histopathological evaluation of endometriotic implant. A – Well-preserved superficial epithelium and elevated stromal vessel density 
(Group 1); B – Evident stromal fibrosis, mild leukocyte infiltration and moderate preserved epithelium (Group 2); C – Congestion in sub-ep-
ithelial stroma and mild fibrosis (Group 3); D – [+] fibrosis in Group 1; E – [++] fibrosis in Group 3; F – [+++] fibrosis in sub-epithelial 
stroma of Group 2.
A-C: H&E staining, Magnification: ×100, Scale bar: 200 micrometer; D-F: Masson’s Trichrome staining, Magnification: ×200, Scale bar: 
100 micrometer.
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sue. Well-preserved epithelium, Grade 3; leukocyte in-
filtration and moderately protected epithelium, Grade 2; 
slightly preserved, very infrequently observed epitheli-
um, Grade 1; disappearance of epithelial line, Grade 0 
(16). According to this scoring system, lower scores 
shows impaired histological structure. Sections stained 
by Masson’s trichrome for observing the fibrosis inten-
sity were assessed by the method described by Erdemir 
et al (19). The collagen density in the samples obtained 
from implanted tissues was assessed and graded on scales 
Figure 3. A – Comparison of endometriotic implant volumes (Y axis 
represents the implant volumes in mm3); B – Comparison of histo-
pathological scores among medication steps (Y axis represents the 
histopathological scores); C – Comparison of fibrosis levels among 
medication steps (Y axis represents the fibrosis level).
Group 1; Control group, Group 2; Amygdalin group, Group 3; 
Leuprolide acetate group.
Data are given as means.
All other p values among medication steps into each group are 
>0.05.
Table 1. Histopathologic comparison of the endometriotic implants among the groups







Endometriotic foci volumes (mm3)
Before treatment 34.16±4.55 32.77±6.85 33.64±7.81 0.561 0.963 0.677
After treatment 28.35±7.47 13.59±7.75 13.13±6.64 0.002 0.001 0.813
After estradiol medication 30.85±8.15 12.72±8.56 25.97±7.65 0.002 0.173 0.007
Histopathological scores
Before treatment 2.33±0.86 2.44±0.72 2.44±1.01 0.964 0.783 0.734
After treatment 2.11±1.05 1.66±1.05 2.00±1.00 0.156 0.729 0.33
After estradiol medication 2.44±0.52 1.77±0.83 2.55±0.52 0.072 0.647 0.042
Fibrosis levels
Before treatment 1.33±0.50 1.66±0.70 1.60±0.69 0.172 0.399 0.565
After treatment 1.44±0.52 1.88±0.78 2.10±0.73 0.121 0.05 0.776
After estradiol medication 1.55±0.72 2.22±0.83 1.90±0.73 0.091 0.288 0.36
* Multiple comparisons were completed using one-way ANOVA test, posthoc analysis were conducted by Tukey’s HSD test.
Bonferrroni corrected p value was used for significance as p < 0.016. Group 1; Control group, Group 2; Amygdalin group, Group 3; Leuprolide acetate 
group. Data are given as means ± standard deviation.
The significance between the groups:
p1; group 1 – group 2, p2; group 1 – group 3, p3; group 2 – group 3
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ranging from 1+, the lowest density collagen, to 4+, the 
highest density collagen ratios under light microscopy 
(×400).
Statistical analysis
All analyses were performed using the Statistical Pack-
age for Social Sciences (SPSS Inc., Chicago, IL) version 
20.0 program. Multiple comparisons were conducted by 
one-way ANOVA test and posthoc analysis using Tukey’s 
HSD test. Continuous variables were expressed as means 
± standard deviation. Bonferrroni corrected p value was 
used for all analysis as p < 0.016.
RESULTS
Endometriosis was successfully induced in all groups. 
The mean (initial) weight of the rats after grouping was 
272.8 grams and 274.7 grams in Group 2 and 3, and 
269.2 grams in Group 1 (p > 0.05). No complications 
were observed among rats; however, one rat in Group 1 
died during the study period.
The endometriotic implant volumes were presented in 
Table 1. Microscopic evaluation of the sections among 
groups was shown in Figure 2 (A, B, C, D, E, F). After 
amygdalin or leuprolide acetate treatment, the endome-
triotic implant volumes in Group 1, Group 2 and Group 
3 were 28.35mm3, 13.59mm3 and 13.13mm3, respec-
tively. The endometriotic implant volumes after amygda-
lin or leuprolide acetate treatment in Group 2 and Group 
3 were significantly lower than in Group 1 (p = 0.002 and 
p = 0.001, respectively). After estradiol medication, the 
implant volume in Group 2 was significantly lower com-
pared to Group 1 and Group 3 (p=0.002 and p=0.007, 
respectively). The implant volumes in Group 2 progres-
sively decreased from the beginning of the amygdalin 
treatment to the end of the estradiol medication (p 
=0.012, p = 0.005; Figure 3A). The endometriotic implant 
volumes in Group 3 were significantly lowered after leu-
prolide treatment compared to the beginning of the treat-
ment (p = 0.007; Figure 3A). The mean histopathological 
scores were presented in Table 1. The fibrosis levels were 
not significantly different among the groups (p > 0.05; 
Table 1).
DISCUSSION
The present study revealed that amygdalin apparently 
lowered the volumes of the endometriotic implant com-
pared to leuprolide acetate after estradiol medication. Ad-
ditionally, a clinically evident decrease in histopathologi-
cal score was observed by amygdalin compared to 
leuprolide acetate treatment after estradiol medication. 
Several drugs have been used for the endometriosis ther-
apy in the clinical setting (8). However, none could pro-
vide a stable long-term benefit and recurrence rates have 
been found to be high after ceasing of treatment. Simsek 
et al. investigated atosiban (an oxytocin receptor blocking 
agent) and found that atosiban treatment decreased the 
endometriotic implant volumes (13). Recently, Dolapcio-
glu et al. compared the effects of theranekron, medroxy-
progesterone acetate and leuprolide acetate in a rat endo-
metriosis model, and showed that theranekron led to 
improvement in endometriosis and exhibited a declined 
ratio of recurrence (17). Nevertheless, current studies also 
indicated that amygdalin might be helpful for the treat-
ment of fibrosis in the liver and kidney (18). Yang et al. 
reported that amygdalin can suppress fibroblast prolifera-
tion and disrupts the process of renal interstitial fibrosis, 
and they concluded that the possible mechanism behind 
this cascade of events could be the increase in the type I 
collagenase secretion, which restricts fibroblast prolifera-
tion, induction of apoptosis, and suppression of type I 
collagenase by amygdalin (20).
In this context, the present study revealed that amyg-
dalin is superior to leuprolide acetate in reducing the im-
plant volumes and maintaining its consistency by display-
ing no visible signs of recurrent growth after the treatment 
ended. It is reported that amygdalin exhibits its effect by 
excreting cyanide through susceptible cells, resulting in 
cell death by cyanide toxicity. The toxicity of cyanide 
might occur in tissue containing glucosidase enzymes, 
which splits off glucose from amygdalin and prunasin 
(21). In relation, a clinical trial by Brandelli et al. showed 
that women with endometriosis have an increased activ-
ity of glucosidases in the peritoneal fluid (22). Amygdalin 
also leads to slightly increased but not significant fibrosis 
levels compared to initial, and provided this level after the 
end of amygdalin treatment that considered as diminish-
ing of endometriotic implant with no visible signs of re-
current growth. A possible mechanism making a connec-
tion with the previous data is that endometrial tissue in 
the implants could be deteriorated by the cyanide toxic-
ity of the endometriotic cells not the components of the 
connective tissue such as fibroblasts due to the enzymatic 
metabolization of amygdalin by glucosidases. Cyanide 
induced the production of reactive oxygen species pro-
vided the activation of p38 mitogen-activated protein 
kinase and nuclear accumulation of hypoxia-inducible 
factor-1-alpha those lead to apoptosis (23). To the extent 
of our knowledge, this is the first experimental study con-
ducted to determine the effects of amygdalin on endome-
triosis treatment and recurrence, and the first time such 
an observation has been demonstrated in an endometrio-
sis model. Amygdalin is a cyanogenic glycoside, wherein 
cyanide is the main reason of toxicity. The lethal dose is 
estimated to be between 50 – 300 mg for humans while 
taking orally, or a blood level over 3 microg/ml. However, 
oral administration is associated with higher incidence of 
toxicity than intravenous, intraperitoneal, or intramuscu-
lar injection because the human intestinal microflora pos-
sesses enzymes capable of effecting cyanide release. Re-
cent research suggests an oral dose of 0.6 – 1.0 gr can 
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avoid toxicity in humans (24). In contrast, there is no data 
available on the dosage of amygdalin in patients with en-
dometriosis.
It is well-demonstrated that three drugs for the treat-
ment of endometriosis including progestins, GnRH ago-
nists and androgenic agents prevent the proliferation of 
the implants and provide diminished adhesion formation. 
Vercellini et al. reported that the use of GnRH analogs 
prevents the risk of recurrence after surgery in patients 
with moderate or severe endometriosis (25). In contrast, 
some studies have been unsuccessful to show any evidence 
about the effects of post-operative medication in reducing 
endometriosis recurrence (26-39). Recent findings dem-
onstrated that post-surgical hormonal therapy for endo-
metriosis has no improvement on pain relief or pregnan-
cy rates, but a substantial decrease in endometriosis 
recurrence rate solely (30). However, there has been no 
satisfactory evidence found to confirm the effects of hor-
monal suppression therapy and surgical approach on en-
dometriosis. Therefore, the outcomes of the present study 
may provide additional information about the develop-
ment and recurrence of this disease.
There are some limitations in the present study. First, 
this is an experimental study with restricted numbers of 
rats per group. This was related to our ethical rules regard-
ing keeping to the ‘principle of reduction’ in animal ex-
periments; however, studies with larger populations 
would be required to find minimal histopathological dif-
ferences among groups. Second, a subjective scoring sys-
tem was performed to assess the histopathological chang-
es of the endometriotic implant. A standardized 
image-analysis program providing an automated interpre-
tation of histopathological changes would be better to 
meet with a more accurate result, which currently is not 
available.
In conclusion, the present study demonstrated that 
amygdalin can suppress the progression of endometriosis 
and its recurrence. Amygdalin might be more beneficial 
both in the treatment and the prevention of visible signs 
of recurrent lesions than leuprolide acetate.
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